Mason Street Advisors’s Immunogen Inc IMGN Stock Holding History

Mason Street Advisors’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-154,800	Closed	-$1.64M	–	1928
2014 Q3	$1.64M	Hold	154,800	–	–	0.01%	1021
2014 Q2	$1.83M	Hold	154,800	–	–	0.01%	992
2014 Q1	$2.31M	Hold	154,800	–	–	0.02%	877
2013 Q4	$2.27M	Hold	154,800	–	–	0.02%	874
2013 Q3	$2.63M	Buy	+154,800	New	+$2.72M	0.03%	584

Other funds holding IMGN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Mason Street Advisors's IMGN Position: Q4 2014 in Review

Mason Street Advisors sold out of Immunogen Inc (IMGN) in Q4 2014, closing a stake of 154,800 shares — an estimated $1.64M sold.

Mason Street Advisors first reported a position in IMGN in Q3 2013 and held it in 5 quarters. The position peaked at $2.63M in Q3 2013. 131 funds tracked by Wall St. Rank hold IMGN as of Q4 2014.

Mason Street Advisors reported no remaining Immunogen Inc position as of Q4 2014 after selling out during the quarter.
Mason Street Advisors sold 154,800 Immunogen Inc shares in Q4 2014, an estimated $1.64M.
Mason Street Advisors first reported a position in Immunogen Inc in Q3 2013 and held it in 5 quarters.
Mason Street Advisors's Immunogen Inc position peaked at $2.63M in Q3 2013.
131 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2014.

Based on Mason Street Advisors's 13F filing for Q4 2014, filed 13 Feb 2015.